ClearPoint Neuro (NASDAQ:CLPT) Director Sells $56,713.74 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Lynnette Fallon sold 5,091 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $11.14, for a total transaction of $56,713.74. Following the completion of the sale, the director directly owned 48,227 shares of the company’s stock, valued at $537,248.78. This represents a 9.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

ClearPoint Neuro Stock Performance

ClearPoint Neuro stock traded up $0.50 during midday trading on Thursday, hitting $11.70. The stock had a trading volume of 404,706 shares, compared to its average volume of 719,147. The firm’s fifty day moving average is $10.55 and its two-hundred day moving average is $12.88. The company has a market capitalization of $350.88 million, a PE ratio of -11.58 and a beta of 1.29. ClearPoint Neuro, Inc. has a 52-week low of $8.27 and a 52-week high of $30.10. The company has a current ratio of 5.79, a quick ratio of 4.88 and a debt-to-equity ratio of 2.63.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.The firm had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. On average, research analysts forecast that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. B. Riley Financial increased their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Finally, Stifel Nicolaus began coverage on ClearPoint Neuro in a research report on Friday, May 8th. They set a “buy” rating and a $16.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, ClearPoint Neuro presently has a consensus rating of “Hold” and a consensus price target of $18.00.

Institutional Trading of ClearPoint Neuro

Several institutional investors and hedge funds have recently made changes to their positions in CLPT. Caitong International Asset Management Co. Ltd bought a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $25,000. Huntington National Bank bought a new stake in shares of ClearPoint Neuro in the third quarter valued at about $44,000. BNP Paribas Financial Markets raised its holdings in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after acquiring an additional 2,143 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of ClearPoint Neuro by 1,079.0% in the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after acquiring an additional 2,158 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of ClearPoint Neuro in the second quarter valued at about $35,000. 30.08% of the stock is currently owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.